IBB iShares Biotechnology ETF
ICE Biotechnology TR USD

NAV as of 27-Mar-2023

126.0478

4 Week: 121.97 - 130.52

52 Week: 105.82 - 138.43

Latest Closing Price

126.03

Premium / Discount

-0.11

Expense Ratio

0.44%

Investment Objective

The investment seeks to track the investment results of the ICE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Main Fund Characteristics

Fund Manager:
iShares
Asset Under Management:
7,948,191,312
Launch Date:
04/02/2001
Asset Class:
Equity
Replication Method:
Physical-Sample
Number of Holdings:
276
Trading Currency:
USD
Style:
Mid Blend
Region/Sector/Strategy:
N.A / Healthcare / N.A
Exchange:
NASDAQ

Performance

Period Performance Returns(%) Volatility(%) Risk Adjusted Performance
YTD-4.011.19-3.36
1 Day0.130.000.00
1 Week0.142.940.05
1 Month-0.666.20-0.11
3 Months-2.519.56-0.26
6 Months9.7615.880.61
1 Year-1.6627.04-0.06
2 Years-15.5035.07-0.44
3 Years20.3644.410.46
5 Years19.8957.610.35
10 Years-20.12135.74-0.15

Price History

-

Annual Performance Return

2013201420152016201720182019202020212022
Price (%) 65.471334.129311.4682-21.530321.2011-9.139324.746725.90130.9906-13.5920
Nav (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000
Rank 4.000015.000021.000092.000063.000083.000049.000039.000073.000059.0000

Dividend Frequency

Lastest Dividend

Ex Date Payment Date Dividend Payout per unit
22/03/202328/03/20230.0646
12/12/202218/12/20220.1014
25/09/202229/09/20220.1586
08/06/202214/06/20220.0305
23/03/202229/03/20220.1176
12/12/202116/12/20210.0413
23/09/202129/09/20210.1244
09/06/202115/06/20210.0232
24/03/202130/03/20210.1311
26/03/202030/03/20200.0554

Portfolio Data

Total Number of Holdings: 276

Number of Bond Holdings: 0

Number of Equity Holdings: 269

Total Market Value: 7,948,191,312

Portfolio Composition

Top 10 Holdings

% Portfolio Weight Shares Owned Shares Changed Market Value
1Gilead Sciences Inc7.433911,270,70687,050661,815,872

Country Exposure

Regional Exposure

America

Greater Europe

Greater Asia

Market Classification

Market Capitalization

Size% of portfolio
Giant1.70
Large49.02
Medium29.32
Small11.90
Micro7.85

Equity Style Box Breakdown

000Large
000Mid
000Small
ValueBlendGrowth

Value Measures

Price/Prospective Earnings*

17.3293

Price/Book*

3.8801

Price/Sales*

3.4271

Price/Cash Flow*

14.3882

Dividend Yield*

0.6572

Growth Measures

Long-Term Earnings

8.7359

Historical Earnings

7.8294

Sales Growth

16.8996

Cash-Flow Growth

10.5885

Book-Value Growth

9.6061

*Forward-looking based on historical data.

Equity Sector

Number of Bond Holdings

0

Bond Statitics

DetailValue
Average Effective Duration0
Average Effective Maturity (Years)*0
Average Credit Quality0
Average Weighted Coupon*0
Average Weighted Price*0

Bond Style Box Breakdown

000HighQuality
000Med
000Low
LtdModExt
Interest-Rate Sensitivity

Credit Quality

Type% Bonds
N.A

Bond Sector

Type
% Bonds

Bond Maturity

% Bonds
N.A

Data Source: Morningstar

© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:

(1) include the proprietary information of Morningstar and Morningstar’s third party licensors;
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.

Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.